The National Agency for Food and Drug Administration and Control has finally approved the use of chloroquine for COVID-19 patients who at the early stage.
However, Mojisola Adeyeye, director-general of NAFDAC while speaking on Tuesday during a virtual news conference in Abuja, stated research has shown that chloroquine is effective for the treatment of COVID-19 at the early stage of infection.
She also revealed that chloroquine can be used prophylactically and that countries like Ghana and Senegal have also embraced the clinical use of chloroquine for treatment.
She added that it is not only one drug that is effective for COVID-19 treatment but that it depends on the stage and the phases of the disease.
“On March 20, this year, I had a press briefing. At that time, people did not understand what clinical trial treatment meant. Once they hear treatment, they think you can use it anyhow. But clinical trial treatment is a research study to see whether the drug will work or not.
“In the press briefing, I said I was going through literature to see what others have done and I saw in a particular literature, a reliable publication of an article, about chloroquine and remdesivir.